Related Experiment Video
Updated: Apr 18, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
549
Genetic polymorphisms and non-small-cell lung cancer: future paradigms
Ramon Andrade Bezerra de Mello1
1Serviço de Oncologia Médica, Instituto Português de Oncologia Francisco Gentil, Porto, Portugal.
Einstein (Sao Paulo, Brazil)
|January 29, 2015
Summary
Genetic polymorphisms are key in non-small cell lung cancer research. This study explores their role and identifies new biomarkers for lung cancer risk and patient outcomes.
Area of Science:
- Oncology
- Genetics
- Translational Research
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Understanding the genetic underpinnings of NSCLC is crucial for improving patient outcomes.
- Translational research aims to bridge the gap between laboratory discoveries and clinical applications in NSCLC.
Purpose of the Study:
- To review current challenges and advancements in the study of genetic polymorphisms in NSCLC.
- To explore novel genetic biomarkers for predicting lung cancer risk.
- To identify potential biomarkers that can inform prognosis in non-small cell lung cancer patients.
Main Methods:
- Literature review of recent studies on genetic polymorphisms in NSCLC.
- Analysis of data linking specific genetic variations to lung cancer susceptibility.
- Evaluation of emerging biomarkers for their potential clinical utility in risk assessment and prognosis.
Main Results:
- Genetic polymorphisms present complex interactions influencing NSCLC development and progression.
- Several genetic markers show promise in stratifying individuals by lung cancer risk.
- Biomarker candidates are emerging for predicting treatment response and patient survival.
Conclusions:
- Genetic polymorphism research is vital for advancing personalized medicine in NSCLC.
- Further validation of identified biomarkers is necessary for clinical implementation.
- Integrating genetic insights can significantly improve lung cancer prevention and management strategies.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
98
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:29Pharmacogenetics and Pharmacogenomics: Overview
202
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
202